System and method for diagnosis of neuropsychiatric disorders
View Patent ↗An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen for or diagnose subjects at high risk for developing a psychiatric, neuropsychiatric, or neurological disorders. The assay of the GCH1 genotype, with or without biopterin or a BH4 or BH4 system assay, may also be used to determine antipsychotic or mood stabilizer medication, as well as other treatments. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.
1. A method of identifying a subject at risk for schizophrenia or schizoaffective disorder, comprising:
determining a GTP cyclohydrolase I (GCH1) −959nt G/A genotype of the subject from a biological sample taken from the subject;
determining the presence of an A allele of the GCH1 −959nt G/A genotype;
determining a biopterin level of the sublect; and
determining that the subject has an increased risk or predisposition to schizophrenia or a schizoaffective disorder based on the biopterin level and the presence of the A allele of the GCH1 −959nt G/A genotype.
2. The method of claim 1 , wherein the step of determining that the subject has an increased risk or predisposition to schizophrenia or a schizoaffective disorder further comprises the step of determining the allele dose of the “A” allele of the GCH1 −959nt G/A GCH1 genotype.
3. The method of claim 1 , wherein the step of determining a GTP cyclohydrolase I (GCH1) −959nt G/A genotype of the subject comprises obtaining a biological sample from the subject, amplifying a genomic region encompassing the G/A genotype, and producing a visual representation of the genomic region.
4. The method of claim 1 , further comprising:
determining a biopterin level from a plasma sample taken from the subject; and
confirming the determination that the subject has an increased risk or predisposition to schizophrenia or a schizoaffective disorder if the subject's biopterin level is below normal.